title: Decreased mitochondrial SIRT3 expression is a potential molecular biomarker associated with poor outcome in breast cancer.
abstract: SIRT3 is a genomically expressed, mitochondrial localized tumor suppressor protein where it directs multiple metabolic processes by deacetylating downstream protein substrates. Genetic deletion of Sirt3 in mice leads to the spontaneous development of mammary tumors starting at 1 year, and decreased SIRT3 messenger RNA has been observed in several human tumors including breast malignancies. In this investigation, we assessed SIRT3 expression in human breast cancer tissue microarray and examined the relationship between SIRT3 expression and outcome in patients with breast cancer. SIRT3 protein expression is significantly lower in neoplastic compared with normal breast epithelium, including normal epithelium adjacent to tumors. Patients with breast cancer in the lowest quartile of SIRT3 expression had a significantly shorter locoregional relapse-free survival (hazard ratio, 0.53 [0.47-0.61]; log-rank P = 0). Notably, low SIRT3 expression was associated with reduced locoregional relapse-free survival in all breast cancer subtypes analyzed, including ER+, ER-, HER2+, and basal subtypes (hazard ratios, 0.44-0.65; log-rank P = 0-.0019). These results highlight the importance of the SIRT3 as a tumor suppressor protein in breast cancer and suggest that SIRT3 may be a potential molecular biomarker to identify high-risk patients across all molecular subtypes of breast cancer.
authors.affiliation: Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37215.
authors.forename: Mohamed Mokhtar
authors.initials: MM
authors.lastname: Desouki
authors.affiliation: Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37215.
authors.forename: Irina
authors.initials: I
authors.lastname: Doubinskaia
authors.affiliation: Department of Radiation Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611.
authors.forename: David
authors.initials: D
authors.lastname: Gius
authors.affiliation: Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37215; Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, TN 37215. Electronic address: sarki.abdulkadir@northwestern.edu.
authors.forename: Sarki A
authors.initials: SA
authors.lastname: Abdulkadir
mesh_terms: D014408:Biomarkers, Tumor; D001943:Breast Neoplasms / Q000235:genetics / Q000401:mortality / Q000473:pathology / Q000503:physiopathology*; D005260:Female; D006801:Humans; D008875:Middle Aged; D008928:Mitochondria / Q000378:metabolism*; D011379:Prognosis; D056566:Sirtuin 3 / Q000096:biosynthesis*
chemical_list: D014408:Biomarkers, Tumor; C466093:SIRT3 protein, human; D056566:Sirtuin 3
keywords: Breast cancer; Clinical outcomes; Metabolism; Mitochondria; Sirt3; Sirtuins
references.citation: Oncogene. 2013 Jul 4;32(27):3274-85
references.pmid: 22907432
references.citation: Cancer Cell. 2011 Mar 8;19(3):416-28
references.pmid: 21397863
references.citation: Oncol Rep. 2013 Sep;30(3):1323-8
references.pmid: 23842789
references.citation: Hum Pathol. 2000 Apr;31(4):443-7
references.pmid: 10821491
references.citation: Genes Dev. 1999 Oct 1;13(19):2570-80
references.pmid: 10521401
references.citation: J Clin Oncol. 2005 Oct 10;23(29):7350-60
references.pmid: 16145060
references.citation: J Clin Invest. 2009 Sep;119(9):2758-71
references.pmid: 19652361
references.citation: Breast Cancer Res Treat. 2009 Dec;118(3):433-41
references.pmid: 19052860
references.citation: Mol Cell. 2010 Dec 22;40(6):893-904
references.pmid: 21172655
references.citation: Diabetes. 2008 Nov;57(11):2933-42
references.pmid: 18716044
references.citation: Genes Dev. 2000 May 1;14(9):1021-6
references.pmid: 10809662
references.citation: Nature. 2010 Mar 4;464(7285):121-5
references.pmid: 20203611
references.citation: J Gerontol. 1956 Jul;11(3):298-300
references.pmid: 13332224
references.citation: Biochem J. 2008 Apr 15;411(2):e11-3
references.pmid: 18363549
references.citation: Am J Clin Pathol. 2005 Jan;123(1):21-7
references.pmid: 15762276
references.citation: Int J Mol Sci. 2011;12(9):6226-39
references.pmid: 22016654
references.citation: Psychol Sci. 2001 Mar;12(2):163-70
references.pmid: 11340927
references.citation: Mol Cell. 2007 Oct 26;28(2):277-90
references.pmid: 17964266
references.citation: Arch Pathol Lab Med. 2010 Jun;134(6):907-22
references.pmid: 20524868
references.citation: Clin Cancer Res. 2012 Apr 1;18(7):1947-53
references.pmid: 22317764
references.citation: Nature. 2009 Jul 30;460(7255):587-91
references.pmid: 19641587
references.citation: Int J Biochem Cell Biol. 2007;39(1):44-84
references.pmid: 16978905
references.citation: Cancer Metastasis Rev. 2004 Aug-Dec;23(3-4):311-22
references.pmid: 15197331
references.citation: Biochem Biophys Res Commun. 2000 Jul 5;273(2):793-8
references.pmid: 10873683
references.citation: Cancer Cell. 2010 Jan 19;17(1):41-52
references.pmid: 20129246
references.citation: Nature. 2000 Feb 17;403(6771):795-800
references.pmid: 10693811
references.citation: Cell. 2006 Jul 28;126(2):257-68
references.pmid: 16873059
references.citation: Cancer Cell. 2011 Oct 18;20(4):487-99
references.pmid: 22014574
references.citation: Cancer. 1997 Oct 1;80(7):1284-93
references.pmid: 9317181